Investigator Initiated Ph 2 Trial for Neoadjuvant Muzastotug (ADG126) in CRC Announced
“The foundation for this neoadjuvant study is supported by the compelling combination efficacy and safety profile of ADG126 with pembrolizumab in late-stage MSS CRC patients,” said Peter Luo, Chairman, CEO, and President of R&D at Adagene. “We believe that advancing immunotherapy into the curative neoadjuvant setting holds significant promise. By combining CTLA-4-mediated T regulatory cell depletion with anti-PD-1’s ability to reinvigorate exhausted T cells, this approach restores anti-tumor immunity, offering patients a head start and the potential for long-term clinical benefits.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.